Opportunity
Federal Register #2026-22749
SEC notice on Daxor Corporation’s application to cease investment-company registration
Buyer
Securities and Exchange Commission
Posted
November 09, 2026
Identifier
2026-22749
The Securities and Exchange Commission published a regulatory notice about Daxor Corporation’s application to cease being registered as an investment company. - Government agency: U.S. Securities and Exchange Commission (SEC); no sub-agency or purchasing office is identified. - Company named: Daxor Corporation, which describes itself as a radiopharmaceutical company and medical device manufacturer. - Daxor mentions its Volumex Test Kits and BVA Companion Analyzer as products in its business, but they are not being solicited for purchase; no quantities or part numbers are provided. - The notice invites interested persons to request a hearing. This is not a procurement opportunity, and no products or services, contract value, or performance period are specified.
Description
The Securities and Exchange Commission notice concerns Daxor Corporation’s application for deregistration under section 8(f) of the Investment Company Act of 1940. Daxor requests an order declaring that it has ceased to be an investment company. The application was filed on February 9, 2026, and amended on May 21, June 17, September 4, and October 9, 2026. Interested persons may request a hearing by November 30, 2026.